Link Medicine raises $40 million in Series C financing
The round was funded by two biotechnology investors – Clarus Ventures and SV Life Sciences. Adam Rosenberg, CEO of Link Medicine, said: “Link Medicine was established to bring
The US Food and Drug Administration (FDA) has declined to approve Unicycive Therapeutics’ resubmitted new drug application (NDA) for oxylanthanum carbonate (OLC) to treat hyperphosphatemia in chronic kidney disease (CKD) patients on dialysis.